SCHEMBL15071150

SCHEMBL15071150

Cc1cccc(C(C)c2c(C)nc3ccc(C(=O)N4CCCCC4)cn23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 9/20 0.49
▸ F2RL1 P55085 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GBA1 P04062 1/20 0.40
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CHRNA1 P02708 1/20 0.38
▸ CHRNG P07510 1/20 0.38
▸ CHRNB1 P11230 1/20 0.38
▸ CHRNB2 P17787 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ CHRNB4 P30926 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15071148 0.90 HPGD (0.49) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15074830 0.85 HPGD (0.44) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL31522 0.81 F2RL1 (0.44) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL31560 0.79 F2RL1 (0.63) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15071149 0.78 HPGD (0.58) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15071141 0.78 F2RL1 (0.61) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15071137 0.78 F2RL1 (0.59) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15071129 0.77 HPGD (0.50) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15050221 0.74 F2RL1 (0.53) HPGDF2RL1ALDH1A1NPC1GLA
SCHEMBL15071099 0.73 F2RL1 (0.52) HPGDF2RL1ALDH1A1NPC1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 HPGD 80/4885F2RL1 1/4885ALDH1A1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback